Autistic phenotypes and genetic testing: state-of-the-art for the clinical geneticist

C Lintas, A M Persico

ABSTRACT

Autism spectrum disorders represent a group of developmental disorders with strong genetic underpinnings. Several cytogenetic abnormalities or de novo mutations able to cause autism have recently been uncovered. In this study, the literature was reviewed to highlight genotype–phenotype correlations between causal gene mutations or cytogenetic abnormalities and behavioural or morphological phenotypes. Based on this information, a set of practical guidelines is proposed to help clinical geneticists pursue targeted genetic testing for patients with autism whose clinical phenotype is suggestive of a specific genetic or genomic aetiology.

Autism spectrum disorders (ASDs) represent a heterogeneous group of neurodevelopmental disorders characterised by social and communication deficits, accompanied by repetitive and stereotyped behaviours, with onset before 3 years of age. From a diagnostic standpoint, ASDs coincide with the Diagnostic and statistical manual of mental disorders, 4th edition (DSM-IV) criteria for pervasive developmental disorders, including autistic disorder, Asperger syndrome, childhood disintegrative disorder, Rett syndrome and “pervasive developmental disorder not otherwise specified” (PDD-NOS). However, the concept of ASD is somewhat complementary to DSM-IV categorical diagnoses, because it underlines that autistic-like traits and behaviours represent a continual spectrum rather than clinically defined diagnostic categories. The male:female sex ratio for autistic disorder is 4:1, implying an involvement of the X chromosome and/or imprinting mechanisms. Autism is associated with seizures and mental retardation (MR) in up to 30% and 80% of cases, respectively. A prenatal origin of the disease is supported by neuroanatomical and neuroimaging studies, showing abnormalities stemming from disturbed neurodevelopmental processes physiologically occurring during the first and second trimester of pregnancy.

Genetics strongly contributes to the pathogenesis underlying ASDs. Rett syndrome, a monogenic disorder affecting female carriers of mutations in the MeCP2 gene, has been described in detail previously. In this review, we focus on the remaining ASDs and especially on autistic disorder, the neuropsychiatric disorder with the highest monozygotic twin concordance rate (75–95%), the highest heritability (>90%, as estimated by twin studies) and a noticeable sibling recurrence risk (5–6% for non-syndromic autism). In addition the presence of mild autistic traits in first-degree relatives of patients with autism points towards a strong genetic component in ASD. Linkage and association studies have identified numerous susceptibility genes, located on various chromosomes, especially 2q, 7q, 15q and the X chromosome. 9 The clinical heterogeneity of ASD probably reflects the complexity of its genetic underpinnings, involving multiple contributing loci, genetic heterogeneity, epistasis and gene–environment interactions. Interestingly, epidemiological studies reported an incidence of 2–5 in 10 000 newborn babies before 1985, whereas studies performed after the year 2000 converge upon rates of ASD as high as 20–60 in 10 000. This increase may stem from the use of broader diagnostic criteria and increased attention by the medical community, but a real increase in incidence of ASD due to environmental and epigenetic factors acting upon a genetically vulnerable background is also likely.

Genetic screens represent a powerful tool when dealing with monogenic mendelian disorders, characterised by direct genotype–phenotype correlations. In the case of complex disorders, such as ASD, widespread genetic testing would not only be expensive and time-consuming, but also generally inappropriate due to the aetiological complexity described above. Nonetheless, there are at least two instances where genetic testing can be successfully used in complex disorder: to evaluate the degree of genetic susceptibility to a certain disease and to identify rare monogenic or cytogenetic forms of the disease. The appropriate use of genetic testing in these two instances is good clinical practice for the following reasons: (1) the identification of susceptibility variants can allow the implementation of prevention programmes, as exemplified by familial breast and ovarian cancers involving BRCA1 and BRCA2 mutations, or familial colon cancer; (2) the identification of the exact genetic cause of an otherwise unexplained disease, especially when it affects children, can significantly reduce the levels of guilt and anxiety in parents and improve their compliance with medical interventions and to rehabilitation programmes.

During the past few years, genetic research in ASDs has begun achieving some important successes, including the identification of several vulnerability loci and of a few cytogenetic abnormalities or single-base mutations able to cause autism (see below). In order to transfer this recently acquired knowledge into clinical practice, it is critical to define a set of phenotypic inclusion criteria that must be met by affected probands to justify their enrolment in a specific genetic testing programme. Accordingly, these genetic screening
SYNDROMIC AUTISM

Syndromic autism (ASD associated with a known cause) represents approximately 10% of all ASD cases and is often associated with malformations and/or dysmorphic features. Unlike “idiopathic” or “primary” ASD, syndromic autism shows an equal male:female sex ratio. Syndromic autism can be associated with well-known genetic or genomic disorders (including fragile X syndrome, neurofibromatosis, tuberous sclerosis, untreated phenylketonuria, and Angelman, Cornelia de Lange and Down syndromes), with de novo chromosomal rearrangements detectable by karyotyping (duplication of the maternal 15q11-13 region, deletions of chromosome 2q37, 7q31, 22q11 and microdeletions of chromosome 22q11.2) and with rare environmental events (prenatal central nervous system infection by rubella or cytomegalovirus, prenatal exposure to valproic acid or thalidomide).

The recent advent of array-based high-resolution genomic analysis has dramatically increased the power to detect small de novo genomic deletions and duplications, down to a few kilobases in size, well below the threshold of detection by standard chromosomal banding and karyotyping techniques. At least four independent genome-wide studies have identified de novo microdeletions, microduplications or copy number variants (CNVs) associated with autism using array-comparative genome hybridisation (CGH) techniques using either bacterial artificial chromosome (BAC) or single-nucleotide polymorphism arrays. Jacquemont et al found that 8 of 29 (27.5%) patients with autism carrying microdeletions or microduplications of 1.4–16.0 Mb in size, including six de novo chromosomal rearrangements presented with dysmorphic facial features. Sebat et al. found de novo CNVs in 10% of trios with one affected child (12 of 118) and in 1% of normal trios (2 of 196). Although the clinical characteristics of de novo CNV carriers were not described in detail, they were interestingly not found to be at increased risk of MR and some were apparently diagnosed with Asperger syndrome, suggesting that CNVs may also be associated with milder forms of autism, perhaps not accompanied by dysmorphic features. Marshall et al. assessed 427 unrelated patients with ASD and 500 controls, finding 27 (6.8%) cases carrying de novo CNVs, which may be especially present in simplex (4/56 = 7.1%) rather than in multiplex (1/49 = 2.0%) families. Many, but not all patients, display dysmorphic features and/or neurological impairment. Christian et al. reported the presence of 7 de novo and 44 inherited CNVs in 597 patients with ASD. The clinical features were not discussed in detail, but no evidence of signs or symptoms shared by patients carrying de novo chromosomal microdeletions or microduplications was reported. Using array-based technologies, others have reported novel and possibly recurrent microdeletion syndromes, affecting regions such as 16p11.2 and 2p15–16.1. These studies have confirmed that CNVs can be associated with a variety of clinical features, including non-ASD behavioural disorders in siblings of patients with autism. Therefore, the presence of malformations, dysmorphic features and/or severe neurological symptoms strongly points toward a possible cytogenetic origin for ASDs, but their absence does not exclude it. The progressive transfer of array-based approaches from the laboratory into clinical practice will enhance our ability to detect an increasing number of submicroscopic de novo chromosomal abnormalities.

GENES INVOLVED IN MONOGENIC FORMS OF AUTISM

Neuroligin 3/4 genes (NLGN3, NLGN4)

Neuroligins are cell-adhesion molecules localised postsynaptically in both glutamatergic (NLGN1, NLGN3, NLGN4) and gamma-aminobutyric acid-ergic (NLGN2) synapses. They interact with presynaptic N-methyl-D-aspartate receptors, triggering the formation of functional presynaptic structures in contacting axons. They also associate with postsynaptic scaffolding proteins, such as SHANK3, also involved in ASD (see below). The NLGN3 and NLGN4 genes, located at human chromosome loci Xq13 and Xq22.33, respectively, have been found to host rare mutations explaining <1% of ASD cases (table 1). Jamain et al. reported a frameshift (D596X in NLGN4) and a missense (R451C in NLGN5) mutation in two unrelated Swedish families, both mutations inherited from unaffected mothers. In vivo studies using D596X or R451C mouse mutants showed increased inhibitory synaptic transmission and impaired social interaction, paralleled by functional studies showing...
defective vesicle- trafficking and synapse- induction properties.26–30 Extensive genetic screens conducted by several groups have confirmed the low frequency of neuroligin mutations among patients with ASD (7/361; 0.8%; table 1). Laumonnier et al31 found a frameshift mutation (D429X in NLGN4) in 13 affected male members of a single pedigree (counted as one instance in table 1, because they are related individuals coming from a single pedigree). Lawson- Yuen et al32 identified a deletion of exons 4–6 of NLGN4 in an boy with autism and in his brother with Tourette syndrome; the mutation was inherited by the mother who also had neuropsychiatric disorders. Yan et al33 reported four other NLGN4 missense mutations in patients with ASD (G99S, K378R, V403M and R704C). However, V403M and R704C were also found in unaffected siblings, suggesting they could represent rare non- synonymous variants rather than true mutations. None of 555 patients with ASD assessed in five other studies were found to carry NLG3 or NLG4 non- synonymous variants.34–38 In contrast, novel splice anonymous variations present in the ASD group, but not in the control sample, were also found in both studies.40 41 However, these variations were inherited from healthy parents and sometimes were also present in unaffected siblings, suggesting that they may confer vulnerability rather than play a dominant role in ASD pathogenesis. Indeed two of the mutations (R12C and R300C) were associated with severe language problems and social interaction difficulties. In vitro overexpression of these variants could explain their presence in other unaffected family members. Alternatively, they may cause the disease by acting synergistically with other susceptibility genes.

It is interesting that both studies reported an inherited 22q13 deletion involving SHANK3 (800 kb in Durand et al39 and 5.2 Mb at 22q13 in Moessner et al40), stemming from a paternal balanced translocation. In both studies, the probands with autism had siblings with partial 22q13 trisomy affected by disorders as different as Asperger syndrome with early language development41 and attention deficit hyperactivity disorder.42 These observations suggest that fine- tuning of SHANK3 gene dosage may be crucial for the development of language and social cognition in humans.

The neurexin 1 gene
Presynaptic neurexins induce postsynaptic differentiation in contacting dendrites, by interacting with their postsynaptic neuroligin partners.43–25 The three neurexin genes (NRXN1, NRXN2 and NRXN3, located at the human chromosome loci 2q32, 11q13 and 14q24.3–q31.1, respectively) have two independent promoters, which determine two mRNA classes: long mRNAs, encoding for α-neurexins and short mRNAs, encoding for β- neurexins.44 A mutational NRXN1β screening conducted by Feng et al45 on 264 patients with ASD identified two heterozygous missense mutations (S14L and T40S) and a GG insertion in position 26 of the corresponding protein (table 3). The two missense mutations were present in 4/264 (1.5%) patients with ASD and not in 729 controls, but they also occurred in first- degree relatives (parents and/or unaffected siblings), who displayed very heterogeneous phenotypes ranging from hyperactivity, depression and/or learning problems to apparently normal behaviour. Similarly, one of two chromosomal rearrangements affecting the NRXN1 gene were also shown to be paternally inherited in one patient.46 The same study also reported two rare missense variants (L18Q and L748I) in 2 of 57 people with ASD.46 People with autism carrying the SI4L mutations apparently have seizures and facial dysmorphism.45 No clinical and family data were reported for patients carrying the insertion. In another study, a de novo heterozygous 300 kb deletion in the coding exons of the NRXN1 gene was found in two affected sisters, who both received a diagnosis of autism.46 However, one girl was reported to be non-verbal, whereas the other had mild language regression.46 In a recent case- control
study by Yan et al, five rare patient-specific variants were identified in 116 ASD individuals whereas only one additional variant (G28A) was also found in controls. Unfortunately, no clinical or family data are available for this study.

The presence of deletions or other mutations also in unaffected siblings of patients with autism and even in controls, suggest that such mutations could confer vulnerability to ASD rather than causing the disease. In addition, the small number of studies performed to date on the putative link between neurexin genes and autism suggest caution in addressing potential genotype–phenotype correlations.

The methyl-CpG-binding protein 2 gene
Methyl-CpG-binding protein 2 (MeCP2) is a transcriptional repressor that binds to methylated CpG dinucleotides generally located at gene promoters and recruits HDAC1 and other proteins involved in chromatin repression. De novo mutations of the MECP2 gene located on chromosome Xq28 occur in 80% of female patients with Rett syndrome, a pervasive developmental disorder generally characterised by regression, autism, microcephaly, stereotyped behaviours, epilepsy and breathing problems, whereas in males, mutations are generally lethal. Some mutations can also result in asymptomatic phenotypes, mild MR and verbal Rett variants. The clinical phenotype depends upon the type of mutation and the specific X-inactivation pattern, which is highly skewed in the presence of mutations affecting X-linked genes, such as NLGN3 and MECP2, but is not significantly skewed in ASD families overall.

Several groups have screened the MECP2 gene for mutations in patients with non-syndromic ASD (table 4). Of 11 studies, 2 have identified de novo MECP2 mutations in female patients with ASD: a de novo splice variant in intron 2 (IVS2 + 2delTAAG), a frameshift mutation (1157del41) and a nonsense mutation (R294X). Two different mutations were identified: a 84C→G mutation results in the introduction of a stop codon in the Turkish person, and a 175–176insG causes a reading frame shift and premature protein truncation in the Saudi Arabian patients. The probands of these families showed a similar phenotype characterised by horizontal gaze abnormalities, deafness, focal weakness, hypoventilation, vascular stereotypies or any of the symptoms characteristic of Rett syndrome; regression was present in one patient, but not in the other two. Another study identified two de novo mutations (R133C and R455X) in girls with ASD fulfilling the criteria for the preserved speech variant of Rett syndrome. Overall, MECP2 mutations are rare in the autistic population, accounting for 0.8–1.3% of cases in the female ASD population (ie, 3/378 or 5/397, respectively, depending whether patients from the Zappella et al study are included (table 4) and not including subjects from the Shibayama et al study for which no male:female ratio is provided). Importantly, female patients with ASD carrying MECP2 mutations appear mentally retarded, but do not display any clinical trait resembling Rett syndrome. Signs and symptoms more typical of Rett syndrome may be of later onset, requiring that female patients with ASD be clinically monitored over time.

The homeobox A1 gene
HOXA1 is a homeobox gene located at human chromosome locus 7p15.3, essential to the development of head and neck structures, including hindbrain, ear, and occipital and hyoid bones. Homozygous recessive stop-codon mutations of this gene have been found in nine people belonging to four consanguineous families from Saudi Arabia and one from Turkey. Two different mutations were identified: a 94C→G mutation results in the introduction of a stop codon in the Turkish person, and a 175–176insG causes a reading frame shift and premature protein truncation in the Saudi Arabian patients. The probands of these families showed a similar phenotype characterised by horizontal gaze abnormalities, deafness, focal weakness, hypoventilation, vascular

---

**Table 2 SHANK3 and autistic spectrum disorders**

<table>
<thead>
<tr>
<th>Reference</th>
<th>Patients with ASD, n</th>
<th>De novo mutations, n (%)</th>
<th>Mutations/deletions</th>
<th>Clinical phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>Durand et al</td>
<td>227</td>
<td>3/227 (1.3)</td>
<td>142 kb del at 22q13, E409X, 800 kb del at 22q13*</td>
<td>Autism with severe language and social deficits</td>
</tr>
<tr>
<td>Moessner et al</td>
<td>400</td>
<td>4/400 (1)</td>
<td>277 kb del at 22q13, 3.2 Mb del at 22q13, 4.36 Mb del at 22q13, G321R</td>
<td>Autism with non-verbal communication and social deficits</td>
</tr>
<tr>
<td>Total</td>
<td>627</td>
<td>7/627 (1.1)</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

ASD, autistic spectrum disorders.

*Parents have a balanced translocation.

---

**Table 3 Neurexin 1 and autistic spectrum disorders**

<table>
<thead>
<tr>
<th>Reference</th>
<th>Patients with ASD, n</th>
<th>De novo mutations, n (%)</th>
<th>Mutations/deletions</th>
<th>Clinical phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feng et al</td>
<td>264 (219M+45F)</td>
<td>0/192 (0)</td>
<td>S14L*, T40S, 26insGG†</td>
<td>Autism with seizures and facial dysmorphism</td>
</tr>
<tr>
<td>The Autism Genome Project Consortium</td>
<td>196</td>
<td>2/196 (0.5)</td>
<td>300 kb del at 2p16</td>
<td>Autism with mild to severe spoken language deficits</td>
</tr>
<tr>
<td>Kim et al</td>
<td>57</td>
<td>0/57 (0)</td>
<td>ins(16;2)(q22.1;p16.1p16.3), t(1;2)(q31.3;p16.3), L180†, L748†</td>
<td>—</td>
</tr>
<tr>
<td>Yan et al</td>
<td>116</td>
<td>0/116 (0)</td>
<td>R8P, L13F, G28A, c1024 +1 G→A, T665†, E715K†</td>
<td>—</td>
</tr>
<tr>
<td>Total</td>
<td>633</td>
<td>1/633 (0.15)</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

ASD, autistic spectrum disorders.

*Mutations found also in other non-affected family members or in controls.
†No clinical and pedigree information available; not specified if occurring de novo.
‡Counted as “1”, because affected members were consanguineous relatives from the same pedigree.
§Rearrangement localised to 750 kb 5’ to the NRXN1 locus.
malformations of the internal carotid arteries and cardiac outflow tract, MR and autism in some, but not all patients: this clinical set of symptoms and malformations was named Bosley–Salih–Alorainy syndrome (BSAS).^65^

**The phosphatase and tensin homologue gene**

*PTEN* is a tumour suppressor gene located on human chromosome 10q25, influencing G1 cell-cycle arrest and apoptosis. In the central nervous system, *PTEN* inactivation results in excessive dendritic and axonal growth with increased numbers of synapses.^64^ Germline mutations resulting in *PTEN* haploinsufficiency thus facilitate cell-cycle progression and oncogenesis, leading to macrocephaly/macroscopy and to cancer development, respectively.^65^ Germline *PTEN* mutations have been found in approximately 80% of individuals diagnosed with Cowden syndrome, accompanied by enhanced risk for breast, endometrial and thyroid malignancies. People with other related hamartoma disorders, such as Bannayan–Riley–Ruvalcaba syndrome, Proteus and Proteus-like syndromes display germline *PTEN* mutations in 60%, 20% and 50% of cases, respectively.\(^66\) In addition, somatic *PTEN* mutations have been found in a variety of human tumours.\(^67\) Interestingly, genetic syndromes due to *PTEN* germline haploinsufficiency, in addition to excessive, dysplastic or neoplastic growth, are often characterised by autism or MR and progressive macrocephaly, as initially reported by Goffin et al.\(^66\) A study by Butler et al^67^ identified three de novo heterozygous *PTEN* germline mutations in 18 (16.6%) people with macrocephaly and autism (table 5). The three newly identified mutations all lead to missense changes in evolutionarily conserved aminoacid residues. Others found *PTEN* mutations in different percentages of macrocephalic patients with ASD\(^68\)–\(^70\) (in one case also displaying polydactyly of both feet).\(^70\)

<table>
<thead>
<tr>
<th>Reference</th>
<th>Patients with ASD, n</th>
<th>De novo mutations, n (%)</th>
<th>Mutations/ deletions</th>
<th>Clinical phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lam et al^65^</td>
<td>21 (all F)</td>
<td>1/21 (4.8)</td>
<td>IVS2+2delTAAG</td>
<td>Autism and MR. No regression, epilepsy or macrocephaly</td>
</tr>
<tr>
<td>Vourch et al^64^</td>
<td>59 (42M,17F)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Beyer et al^67^</td>
<td>202 (154M,48F)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Carney et al^67^</td>
<td>69 (all F)</td>
<td>2/69 (2.9)</td>
<td>1157delA1, R294X</td>
<td>—</td>
</tr>
<tr>
<td>Zappella et al^68^</td>
<td>19 (all F)</td>
<td>2/19 (4.7)</td>
<td>R133C, R453X</td>
<td>—</td>
</tr>
<tr>
<td>Shibayama et al^62^</td>
<td>24†</td>
<td>0/24 (0)</td>
<td>c1639 G→C,* c 6809 T→C,* P376R†</td>
<td>—</td>
</tr>
<tr>
<td>Lobo-Mendez et al^66^</td>
<td>99 (58M,41F)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Li et al^67^</td>
<td>65 (49M,16F)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Yi et al^67^</td>
<td>31 (all M)</td>
<td>0/31 (0)</td>
<td>1′UTR variant*</td>
<td>—</td>
</tr>
<tr>
<td>Harvey et al^67^</td>
<td>401 (266M,135F)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Coutinho et al^67^</td>
<td>172 (141M,31F)</td>
<td>0/172 (0)</td>
<td>12′UTR variants, 2 intronic variants, G206A*</td>
<td>—</td>
</tr>
<tr>
<td>Total</td>
<td>397F, 741M†</td>
<td>5/397 females (1.3), 0/741 males</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

ASD, autistic spectrum disorders; MR, mental retardation; UTR, untranslated region.
*Not specified if occurring de novo; no pedigree information available.
†The study by Shibayama et al did not provide an M:F ratio and was excluded from the total.

The incidence of *PTEN* de novo mutations in these macrocephalic/macroscopic patients with ASD can be estimated at 4.7% (6/126) (table 5). Importantly, these patients are at increased risk of developing a variety of *PTEN*-related cancers during adulthood.

**GUIDELINES FOR GENETIC COUNSELLING**

Based on the information summarised above, we have defined a set of practical guidelines that clinical geneticists should consider, together with recently reviewed ethical issues,\(^72^) when providing genetic counselling to parents of autistic children.

- If a couple has a non-syndromic autistic child, the probability that a second child will also be autistic is approximately 5–6%.
- A karyotype and fragile-X testing must be requested for all patients with ASD.
- Clinicians should be aware that prenatal genetic testing typically raises unrealistic expectations in parents of children with autism because, with the exception of rare gross chromosomal rearrangements, the genetic or genomic anomalies responsible for ASD are not detectable using current prenatal screening methods.
- In the presence of dysmorphic features and evident neurological symptoms, it is reasonable to suspect chromosomal rearrangements even if the karyotype appears normal. Depending upon availability and cost, a BAC or oligo array-based CGH analysis is strongly advised in these cases. As these technologies will become progressively more available, it will be important not to restrict them to patients with dysmorphism, as microdeletions and microduplications are also common among patients with idiopathic, non-dysmorphic ASD.

- Patients with *NLG3* and *NLG4* mutations do not share any specific clinical features and the frequency of these mutations is sufficiently low that widespread screening for neurologin mutations do not seem to be clinically justified.
- For the same reasons and owing to the small number of studies performed to date, widespread screening for the neurexin genes are also not advisable at present.

---

**Table 4 MECP2 and autistic spectrum disorders**

<table>
<thead>
<tr>
<th>Reference</th>
<th>Patients with ASD, n</th>
<th>De novo mutations, n (%)</th>
<th>Mutations/ deletions</th>
<th>Clinical phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lam et al^65^</td>
<td>21 (all F)</td>
<td>1/21 (4.8)</td>
<td>IVS2+2delTAAG</td>
<td>Autism and MR. No regression, epilepsy</td>
</tr>
<tr>
<td>Vourch et al^64^</td>
<td>59 (42M,17F)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Beyer et al^67^</td>
<td>202 (154M,48F)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Carney et al^67^</td>
<td>69 (all F)</td>
<td>2/69 (2.9)</td>
<td>1157delA1, R294X</td>
<td>—</td>
</tr>
<tr>
<td>Zappella et al^68^</td>
<td>19 (all F)</td>
<td>2/19 (4.7)</td>
<td>R133C, R453X</td>
<td>—</td>
</tr>
<tr>
<td>Shibayama et al^62^</td>
<td>24†</td>
<td>0/24 (0)</td>
<td>c1639 G→C,* c 6809 T→C,* P376R†</td>
<td>—</td>
</tr>
<tr>
<td>Lobo-Mendez et al^66</td>
<td>99 (58M,41F)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Li et al^67^</td>
<td>65 (49M,16F)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Yi et al^67^</td>
<td>31 (all M)</td>
<td>0/31 (0)</td>
<td>1′UTR variant*</td>
<td>—</td>
</tr>
<tr>
<td>Harvey et al^67^</td>
<td>401 (266M,135F)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Coutinho et al^67^</td>
<td>172 (141M,31F)</td>
<td>0/172 (0)</td>
<td>12′UTR variants, 2 intronic variants, G206A*</td>
<td>—</td>
</tr>
<tr>
<td>Total</td>
<td>397F, 741M†</td>
<td>5/397 females (1.3), 0/741 males</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

ASD, autistic spectrum disorders; MR, mental retardation; UTR, untranslated region.
*Not specified if occurring de novo; no pedigree information available.
†The study by Shibayama et al did not provide an M:F ratio and was excluded from the total.
Genetic screening programmes for the SHANK3 gene can potentially be implemented for patients with severe verbal and social deficits, bearing in mind that some SHANK3 mutations have also been found to be transmitted to unaffected siblings of ASD probands (see table 1 in Moessner et al\(^\text{64}\)).

MECP2 genetic testing should be performed in all girls with ASD and MR, remembering that clinicians should not expect these patients to bear any resemblance to Rett syndrome (ie, girls with autism carrying MECP2 mutations will have normal head size, a history of regression may be present or absent, and they will usually show no stereotypies or seizures).

HOXA1 mutations are recessive. It is thus reasonable to screen only patients from consanguineous families, when presenting with autism associated with deafness, troncoencephalic anomalies and especially horizontal gaze abnormalities.

The PTEN gene should be screened for mutations in all children with autism and extreme macrocephaly (>3 SD). Because of the tumour susceptibility produced by PTEN haploinsufficiency, it is strongly advised to start an oncological monitoring programme immediately for patients with ASD carrying PTEN mutations.

If the parents of a macrosomic autistic child (carrying no genomic rearrangement or mutation affecting the genes discussed above) decide to have another child, clinicians should monitor weight, height and head circumference of the baby sibling at regular intervals from birth to 2 years of age (ie, during the clinical “latency” phase that precedes the onset of autistic symptoms). If the neonate displays a progressive overgrowth of head and body size compared with age-specific and sex-specific population norms, it is advisable to start an early intervention programme, wherever available, with the aim of stimulating social cognition at 18–24 months of life.

The design of behavioural intervention programmes targeted to address ASD signs and symptoms as early as possible (ie, before the age of 3 years) is being actively pursued in many clinical centres, in order to intervene during the critical period of maximum plasticity in postnatal brain development.\(^\text{50}\) Within this context, working in conjunction with paediatricians and child neuropshiatrists, clinical geneticists can significantly contribute not only to the diagnostic process, but also to successful implementation of the most appropriate behavioural intervention programme. By designing and implementing clinically targeted genetic screens, as proposed in our guidelines, clinical geneticists will provide medically relevant information while decreasing the level of anxiety and guilt in the parents, thereby increasing their compliance with the pharmacological and behavioural treatment of their child with autism. Transferring the latest knowledge from autism genetic research into clinical practice may not yet provide all the definitive answers that investigators and clinicians would have wished to have reached at this time, but can certainly contribute to raise the clinical management of these patients and their families beyond current standards.

**Acknowledgements:** This study was supported by the Italian Ministry for University, Scientific Research and Technology (Programmi di Ricerca di Interesse Nazionale, prot. n.2006058195), the National Alliance for Autism Research (Princeton, NJ), the Cure Autism Now Foundation (Los Angeles, CA) and the Fondation Jerome Lejeune (Paris, France).

**Competing interests:** None declared.

**REFERENCES**


